Webinar June 28, 2012

Andliena Tahiri, Ph.D student at Akershus University Hospital, Norway.

She is a part of the oncogenomic research group that mainly focuses on breast cancer, but recently also melanoma and colon cancer. She has a M.Sc in molecular biology, and her main research focus involves microRNAs and tyrosine kinases in cancer.

 

Topic:Tyrosine kinase activity profiling of metastatic malignant melanoma

 

 

Metastatic melanoma is an aggressive form of skin cancer that is highly resistant to conventional chemotherapy. Thus, novel approaches to improve the current treatment of advanced melanoma are urgently needed. Kinases are key regulators of cellular processes, and since nearly half of the tyrosine kinase complement is implicated in cancer, the information of kinase activity in tumors give important tumor-specific information on affected pathways and potential targets for treatment.
In this study, we performed tyrosine kinase activity profiling of 26 tissue samples obtained from stage IV melanoma patients using Tyrosine Kinase PamChip arrays. Results show that the PTK activity is generally higher in melanoma samples compared to normal skin, with 48 peptides being significantly different in activity between the two groups. After Vemurafenib treatment, a set of 41 peptides could differentiate between BRAFwt and BRAFV600E. Most of the peptides were involved in the MAPK pathway previously identified to be important for the response and resistance to PLX4032. This is indicating that PTK’s involved in the MAPK pathway may serve as important targets for the future treatment of metastatic malignant
melanoma
.

 

 You can review a recording of the webinar here.